Attitudes of health care professionals toward pharmacogenetic testing

Molecular Diagnosis and Therapy

Volumn 15, Issue 2, 2011, Pages 115-122

  Zgheib, Nathalie K ^a   Arawi, Thalia ^a   Mahfouz, Rami A ^a   Sabra, Ramzi ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Diagnostic tests; Ethics; Medical education; Pharmacogenetics

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; ARTICLE; GENETIC ASSOCIATION; GENETIC SCREENING; HEALTH INSURANCE; HEALTH PERSONNEL ATTITUDE; HOMOZYGOSITY; HUMAN; MEDICAL STUDENT; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROFESSIONAL SECRECY; QUESTIONNAIRE; UNIVERSITY HOSPITAL;

EID: 79957802841     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256401     Document Type: Article

References (72)

1. National Human Genome Research Institute. Human Genome Project [online]. Available from URL: http://www.genome.gov/10001772 [Accessed 2011 Mar 28]
2. Hall PA, Reis-Filho JS, Tomlinson IP, et al. An introduction to genes, genomes and disease. J Pathol 2010; 220 (2): 109-13
3. Human Genome Epidemiology Network. HuGENet [online]. Available from URL: http://www.hugenet.org.uk [Accessed 2011 Mar 28]
4. Committee for Proprietary Medicinal Products, European Medicines Agency. Position paper on terminology in pharmacogenetics [online]. Available from URL: http://www.eurogentest.org/documents2/1165308837041-Pharmacogenetics.pdf [Accessed 2011 Mar 28]
5. US Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels [online]. Available from URL: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ ucm083378. htm [Accessed 2011 Mar 28]
6. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19 (8): 2293-301 (Pubitemid 32366982)
7. Rouits E, Boisdron-Celle M, DumontA, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10 (15): 5151-9 (Pubitemid 39099790)
8. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353 (9154): 717-9 (Pubitemid 29103806)
9. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287 (13): 1690-8 (Pubitemid 34289221)
10. Hopkins MM, Ibarreta D, Gaisser S, et al. Putting pharmacogenetics into practice. Nat Biotechnol 2006; 24 (4): 403-10
11. Gurwitz D, Zika E, Hopkins MM, et al. Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 2009; 12 (3): 134-41
12. PharmGKB. Pharmacogenomics knowledge base [online]. Available from URL: http://www.pharmgkb.org/ [Accessed 2011 Mar 28]
13. Ruano G, Collins JM, Dorner AJ, et al. Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics 2004; 5 (5): 513-7 (Pubitemid 39023068)
14. Vladutiu GD. The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality? Mol Genet Metab 2008; 93 (1): 1-4
15. Van DJ, Bolt I, Kalis A, et al. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18 (4): 303-21 (Pubitemid 38988454)
16. Paul NW, Fangerau H. Why should we bother? Ethical and social issues in individualized medicine. Curr Drug Targets 2006; 7 (12): 1721-7 (Pubitemid 44873733)
17. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues [online]. Available from URL: http://www.nuffieldbioethics.org/sites/default/files/ Pharmacogenetics%20Report.pdf [Accessed 2011 Mar 28]
18. Independent Expert Group, European Commission. Ethical, legal and social aspects of genetic testing: research, development and clinical applications [online]. Available from URL: http://ec.europa.eu/research/conferences/2004/ genetic/pdf/report-en.pdf [Accessed 2011 May 6]
19. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429 (6990): 464-8 (Pubitemid 38715141)
20. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360 (8): 753-64
21. Dong XW, Zheng Q, Zhu MM, et al. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol 2010; 16 (25): 3187-95
22. Centers for Disease Control and Prevention. Genomic testing: ACCE model list of 44 targeted questions aimed at a comprehensive review of genetic testing [online]. Available from URL: http://www.cdc.gov/genomics/gtesting/acce/acce- proj.htm [Accessed 2011 Mar 28]
23. Center for Devices and Radiologic Health [CDER], US Food and Drug Administration. Guidance for industry and FDA staff: pharmacogenetic tests and genetic tests for heritable markers [online]. Available from URL: http:// www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm071075.pdf [Accessed 2011 Mar 28]
24. Mallal S, Phillips E,CarosiG, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358 (6): 568-79
25. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83 (3): 460-70 (Pubitemid 351272635)
26. Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91 (6): 1123-8 (Pubitemid 38821268)
27. Nunnelee JD. Review of an article: the International Warfarin Pharmacogenetics Consortium(2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64.
28. J Vasc Nurs 2009; 27 (4): 109
29. Breckenridge A, Lindpaintner K, Lipton P, et al. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 2004; 5 (9): 676-80 (Pubitemid 39150125)
30. Marx-Stolting L. Pharmacogenetics and ethical considerations: why care? Pharmacogenomics J 2007; 7 (5): 293-6
31. Hedgecoe A. Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics 2007; 8 (3): 267-70 (Pubitemid 46477737)
32. Hedgecoe AM. Context, ethics and pharmacogenetics. Stud Hist Philos Biol Biomed Sci 2006; 37 (3): 566-82 (Pubitemid 44356445)
33. Wellcome Trust. Pharmacogenetics - ethical issues: a consultation document by the Nuffield Council on Bioethics. Response of the Wellcome Trust [online]. Available from URL: www.wellcome.ac.uk/stellent/groups/corporatesite/@ policy-communications/documents/web-document/wtd002776.pdf [Accessed 2011 Mar 28]
34. Expert Group, European Commission. 25 recommendations on the ethical, legal and social aspects of genetic testing [online]. Available from URL: http:// ec.europa.eu/research/conferences/2004/genetic/pdf/recommendations-en. pdf [Accessed 2011May 6]
35. European Commission. Polymorphic sequence variants in medicine: technical, social, legal and ethical issues. Pharmacogenetics as an example [draft; online]. Available from URL: https://www.eshg.org/fileadmin/www.eshg. org/ ESHG-IPTSPGX.pdf [Accessed 2011 Mar 28]
36. Secretary's Advisory Committee on Genetics, Health, and Society, Department of Health and Human Services. Realizing the promise of pharmacogenomics: opportunities and challenges [online]. Available from URL: http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS-PGx-report.pdf [Accessed 2011 Mar 28]
37. Egalite N, Ozdemir V, Godard B. Pharmacogenomics research involving racial classification: qualitative research findings on researchers' views, perceptions and attitudes towards socioethical responsibilities. Pharmacogenomics 2007; 8 (9): 1115-26 (Pubitemid 47578221)
38. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS 2009; 13 (1): 43-61
39. Bottis MC. Comment on a view favoring ignorance of genetic information: confidentiality, autonomy, beneficence and the right not to know. Eur J Health Law 2000; 7 (2): 173-83
40. AmericanMedicalAssociation. Principles ofmedical ethics [online].Available from URL: http://www.ama-assn.org/ama/pub/physician- resources/medical-ethics/ code-medical-ethics/principles-medical-ethics.page? [Accessed 2011 Mar 28]
41. Netzer C, Biller-Andorno N. Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 2004; 18 (4): 344-60 (Pubitemid 38988456)
42. Thomas SM. Society and ethics-the genetics of disease. Curr Opin Genet Dev 2004; 14 (3): 287-91
43. Taub S, Morin K, Spillman MA, et al. Managing familial risk in genetic testing. Genet Test 2004; 8 (3): 356-9 (Pubitemid 39586808)
44. Burgess MM, Laberge CM, Knoppers BM. Bioethics for clinicians: 14. Ethics and genetics in medicine. CMAJ 1998; 158 (10): 1309-13
45. Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 2004; 18 (4): 322-42
46. Brockett PL, Tankersley ES. The genetics revolution, economics, ethics, and insurance. J Bus Ethics 1997; 16 (15): 1661-76 (Pubitemid 127349187)
47. Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003; 349 (6): 562-9 (Pubitemid 36951369)
48. Zachry III WM, Armstrong EP. Health care professionals' perceptions of the role of pharmacogenomic data. J Manag Care Pharm 2002; 8 (4): 278-84
49. Tamaoki M, Gushima H, Tsutani K. Awareness survey of parties involved in pharmacogenomics in Japan. Pharmacogenomics 2007; 8 (3): 275-86 (Pubitemid 46477739)
50. Rogausch A, Prause D, Schallenberg A, et al. Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics 2006; 7 (1): 49-59
51. Fargher EA, Eddy C, Newman W, et al. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 2007; 8 (11): 1511-9 (Pubitemid 350286396)
52. Woelderink A, Ibarreta D, Hopkins MM, et al. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J 2006; 6 (1): 3-7 (Pubitemid 43118304)
53. Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997; 277 (10): 832-6
54. Crentsil V. The pharmacogenomics of Alzheimer's disease. Ageing Res Rev 2004; 3 (2): 153-69 (Pubitemid 38232679)
55. Selkoe DJ.Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81 (2): 741-66
56. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008; 52 (1): 131-45 (Pubitemid 351211806)
57. Minihane AM, Jofre-Monseny L, Olano-Martin E, et al. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc 2007; 66 (2): 183-97
58. Talmud PJ, Lewis SJ, Hawe E, et al. No APOEepsilon4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study. Atherosclerosis 2004; 177 (1): 105-12 (Pubitemid 39361144)
59. Liu S, Ma J, Ridker PM, et al. A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 2003; 166 (2): 323-9 (Pubitemid 36071690)
60. Sjogren M, Hesse C, Basun H, et al. Tacrine and rate of progression in Alzheimer's disease: relation to ApoE allele genotype. J Neural Transm 2001; 108 (4): 451-8 (Pubitemid 32703894)
61. Farlow MR, Cyrus PA, Nadel A, et al. Metrifonate treatment of AD: influence of APOE genotype. Neurology 1999; 53 (9): 2010-6
62. Khoueiry N. Introduction to pharmacogenetics: the future prescribing [symposium presentation]. Lebanese Society of Family Medicine 7th Annual Conference: Genetics in Primary Care; 2008 Oct 24-26; Beirut
63. Antoun J, Zgheib NK, Ashkar K. Education may improve the underutilization of genetic services by Middle Eastern primary care practitioners. Genet Test Mol Biomarkers 2010; 14 (4): 447-54
64. US Congress. Genetic Information Nondiscrimination Act of 2008 [H.R. 493; online]. Available from URL: http://www.govtrack.us/congress/billtext. xpd?bill=h110-493 [Accessed 2010 Mar 28]
65. Genetic Services Policy Project. The Genomics and Personalized Medicine Bill of 2006: summary and comment [online]. Available from URL: http://depts.washington.edu/genpol/docs/ObamaGSPP-1pg.pdf [Accessed 2011 Mar 28]
66. US Congress. Human Genome Privacy Act of 1991 [H.R. 2045]. Washington, DC: US Congress, 1991
67. Lebanese Order of Physicians. The law of human genetic examination [in Arabic]. Lebanese Official Journal 2004
68. Kegley JA. An ethical imperative: genetics education for physicians and patients. Med Law 2003; 22 (2): 275-83 (Pubitemid 36833305)
69. Lunshof J. Teaching and practicing pharmacogenomics: a complex matter. Pharmacogenomics 2006; 7 (2): 243-6
70. Buchanan A, Califano A, Kahn J, et al. Pharmacogenetics: ethical issues and policy options. Kennedy Inst Ethics J 2002; 12 (1): 1-15
71. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J 2005; 5 (4): 221-5 (Pubitemid 41131714)
72. Zgheib NK, Ghaddar F, Sabra R. Teaching pharmacogenetics in low and middle-income countries: team based learning and lessons learned at the American University of Beirut. Curr Pharmacogenomics Person Med. In press